William Blair Begins Coverage on Xencor (NASDAQ:XNCR)

William Blair assumed coverage on shares of Xencor (NASDAQ:XNCR) in a research note issued on Monday,Briefing.com Automated Import reports. The firm set an “outperform” rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the company. StockNews.com downgraded Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. Wells Fargo & Company cut their price target on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $33.86.

Xencor Stock Performance

NASDAQ XNCR opened at $9.70 on Monday. Xencor has a fifty-two week low of $7.16 and a fifty-two week high of $27.24. The firm has a market capitalization of $683.48 million, a P/E ratio of -3.03 and a beta of 0.90. The stock’s fifty day moving average is $12.33 and its two-hundred day moving average is $18.72. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The business had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. On average, research analysts anticipate that Xencor will post -3.68 earnings per share for the current year.

Hedge Funds Weigh In On Xencor

Several institutional investors have recently modified their holdings of XNCR. Vanguard Group Inc. grew its position in shares of Xencor by 5.5% in the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company’s stock valued at $184,239,000 after acquiring an additional 418,040 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Xencor by 2.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,036,412 shares of the biopharmaceutical company’s stock valued at $92,758,000 after acquiring an additional 107,350 shares during the last quarter. TCG Crossover Management LLC lifted its holdings in Xencor by 1.0% in the fourth quarter. TCG Crossover Management LLC now owns 2,452,138 shares of the biopharmaceutical company’s stock valued at $56,350,000 after buying an additional 25,000 shares during the period. RTW Investments LP increased its stake in Xencor by 317.9% in the fourth quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company’s stock valued at $55,218,000 after purchasing an additional 1,827,883 shares in the last quarter. Finally, BVF Inc. IL raised its position in shares of Xencor by 169.3% during the fourth quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company’s stock worth $52,596,000 after purchasing an additional 1,438,760 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.